215 related articles for article (PubMed ID: 27605258)
1. A Randomized, Double-blind, Active-Controlled, Multi-center Study of Ilaprazole in the Treatment of Reflux Esophagitis.
Xue Y; Qin X; Zhou L; Lin S; Wang L; Hu H; Xia J
Clin Drug Investig; 2016 Dec; 36(12):985-992. PubMed ID: 27605258
[TBL] [Abstract][Full Text] [Related]
2. A randomized, double blind, controlled, multi center study of Ilaparazole in the treatment of reflux esophagitis-Phase III clinical trial.
Xue Y; Qin X; Zhou L; Lin S; Wang L; Hu H; Xia J
Contemp Clin Trials; 2018 May; 68():67-71. PubMed ID: 29540336
[TBL] [Abstract][Full Text] [Related]
3. Prospective Single Arm Study on the Effect of Ilaprazole in Patients with Heartburn but No Reflux Esophagitis.
Song IJ; Kim HK; Lee NK; Lee SK
Yonsei Med J; 2018 Oct; 59(8):951-959. PubMed ID: 30187702
[TBL] [Abstract][Full Text] [Related]
4. Analysis of 2-Week Data from Two Randomized, Controlled Trials Conducted in Subjects with Frequent Heartburn Treated with Esomeprazole 20 mg.
Katz PO; Le Moigne A; Pollack C
Clin Ther; 2017 May; 39(5):960-970. PubMed ID: 28431766
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of S-pantoprazole 20 mg compared with pantoprazole 40 mg in the treatment of reflux esophagitis: a randomized, double-blind comparative trial.
Cho YK; Choi MG; Bak YT; Rhee PL; Kim SG; Jung HY; Seol SY
Dig Dis Sci; 2012 Dec; 57(12):3189-94. PubMed ID: 22772870
[TBL] [Abstract][Full Text] [Related]
6. [Efficacy and safety of esomeprazole, compared with omeprazole, in maintenance therapy for reflux esophagitis -a phase III, multicenter, randomized, double-blind trial-].
Kinoshita Y; Miwa H; Kasugai K
Nihon Shokakibyo Gakkai Zasshi; 2013 Aug; 110(8):1428-38. PubMed ID: 23912002
[TBL] [Abstract][Full Text] [Related]
7. [Efficacy of esomeprazole compared with omeprazole in reflux esophagitis patients -a phase III, multicenter, randomized, double-blind, parallel-group trial-].
Kinoshita Y; Miwa H; Kasugai K
Nihon Shokakibyo Gakkai Zasshi; 2013 Feb; 110(2):234-42. PubMed ID: 23381211
[TBL] [Abstract][Full Text] [Related]
8. Clinical trial: factors associated with resolution of heartburn in patients with reflux oesophagitis--results from the EXPO study.
Labenz J; Armstrong D; Zetterstrand S; Eklund S; Leodolter A
Aliment Pharmacol Ther; 2009 May; 29(9):959-66. PubMed ID: 19222417
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of HIP1601 (dual delayed-release esomeprazole) 40 mg in erosive esophagitis compared to HGP1705 (delayed-release esomeprazole) 40 mg: a multicenter, randomized, double-blind, non-inferiority study.
Lim H; Park JK; Chung H; Lee SH; Park JM; Park JH; Kim GH; Shin SK; Hong SJ; Lee KJ; Park MI; Jung HK; Kim HS; Sung JK; Jeon SW; Choi SC; Moon JS; Kim N; Park JJ; Hong SH; Kim NY; Jung HY
BMC Gastroenterol; 2023 Dec; 23(1):447. PubMed ID: 38110901
[TBL] [Abstract][Full Text] [Related]
10. Randomised clinical trial: daily pantoprazole magnesium 40 mg vs. esomeprazole 40 mg for gastro-oesophageal reflux disease, assessed by endoscopy and symptoms.
Moraes-Filho JP; Pedroso M; Quigley EM;
Aliment Pharmacol Ther; 2014 Jan; 39(1):47-56. PubMed ID: 24299323
[TBL] [Abstract][Full Text] [Related]
11. Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis.
Castell DO; Kahrilas PJ; Richter JE; Vakil NB; Johnson DA; Zuckerman S; Skammer W; Levine JG
Am J Gastroenterol; 2002 Mar; 97(3):575-83. PubMed ID: 11922549
[TBL] [Abstract][Full Text] [Related]
12. The new proton pump inhibitor esomeprazole is effective as a maintenance therapy in GERD patients with healed erosive oesophagitis: a 6-month, randomized, double-blind, placebo-controlled study of efficacy and safety.
Vakil NB; Shaker R; Johnson DA; Kovacs T; Baerg RD; Hwang C; D'Amico D; Hamelin B
Aliment Pharmacol Ther; 2001 Jul; 15(7):927-35. PubMed ID: 11421866
[TBL] [Abstract][Full Text] [Related]
13. Partial symptom-response to proton pump inhibitors in patients with non-erosive reflux disease or reflux oesophagitis - a post hoc analysis of 5796 patients.
Bytzer P; van Zanten SV; Mattsson H; Wernersson B
Aliment Pharmacol Ther; 2012 Oct; 36(7):635-43. PubMed ID: 22860764
[TBL] [Abstract][Full Text] [Related]
14. A review of the clinical and economic impact of using esomeprazole or lansoprazole for the treatment of erosive esophagitis.
Raghunath AS; Green JR; Edwards SJ
Clin Ther; 2003 Jul; 25(7):2088-101. PubMed ID: 12946553
[TBL] [Abstract][Full Text] [Related]
15. Healing of Erosive Esophagitis and Improvement of Symptoms of Gastroesophageal Reflux Disease After Esomeprazole Treatment in Children 12 to 36 Months Old.
Tolia V; Gilger MA; Barker PN; Illueca M
J Pediatr Gastroenterol Nutr; 2015 Jul; 60 Suppl 1():S31-6. PubMed ID: 26422096
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of twice-daily rabeprazole for reflux esophagitis patients refractory to standard once-daily administration of PPI: the Japan-based TWICE study.
Kinoshita Y; Hongo M;
Am J Gastroenterol; 2012 Apr; 107(4):522-30. PubMed ID: 22433921
[TBL] [Abstract][Full Text] [Related]
17. Comparative effectiveness and acceptability of the FDA-licensed proton pump inhibitors for erosive esophagitis: A PRISMA-compliant network meta-analysis.
Li MJ; Li Q; Sun M; Liu LQ
Medicine (Baltimore); 2017 Sep; 96(39):e8120. PubMed ID: 28953640
[TBL] [Abstract][Full Text] [Related]
18. Healing of Erosive Esophagitis and Improvement of Symptoms of Gastroesophageal Reflux Disease After Esomeprazole Treatment in Children 12 to 36 Months Old.
Tolia V; Gilger MA; Barker PN; Illueca M
J Pediatr Gastroenterol Nutr; 2015 Jul; 60 Suppl 1():S31-6. PubMed ID: 26121348
[TBL] [Abstract][Full Text] [Related]
19. Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial. The Esomeprazole Study Investigators.
Kahrilas PJ; Falk GW; Johnson DA; Schmitt C; Collins DW; Whipple J; D'Amico D; Hamelin B; Joelsson B
Aliment Pharmacol Ther; 2000 Oct; 14(10):1249-58. PubMed ID: 11012468
[TBL] [Abstract][Full Text] [Related]
20. Comparable efficacy of pantoprazole and omeprazole in patients with moderate to severe reflux esophagitis. Results of a multinational study.
Körner T; Schütze K; van Leendert RJ; Fumagalli I; Costa Neves B; Bohuschke M; Gatz G
Digestion; 2003; 67(1-2):6-13. PubMed ID: 12743434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
